Advisor Group Holdings, Inc. Cellectar Biosciences, Inc. Transaction History

Advisor Group Holdings, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	SELL	$3.5 - $6.9 $1,400 - $2,760	-400 Reduced 7.41%	5,000 $2,000
Q3 2021 Nov 05, 2021	SELL	$8.2 - $12.4 $151,101 - $228,494	-18,427 Reduced 77.34%	5,400 $5,000
Q2 2021 Aug 02, 2021	BUY	$11.8 - $18.2 $193,673 - $298,716	16,413 Added 221.38%	23,827 $28,000
Q1 2021 May 13, 2021	BUY	$15.2 - $25.0 $18,118 - $29,800	1,192 Added 19.16%	7,414 $12,000
Q4 2020 Feb 10, 2021	SELL	$11.2 - $27.7 $35,638 - $88,141	-3,182 Reduced 33.84%	6,222 $13,000
Q3 2020 Nov 12, 2020	BUY	$10.6 - $16.6 $99,682 - $156,106	9,404 New	9,404 $11,000

Ticker CLRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 6,114,290
Market Cap $13M
Description
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's ma...

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisor Group Holdings, Inc. with notifications on news.